LobbyingOctapharma USA lobbying by quarter
Octapharma USA's latest lobbying report covers Q2 2026, at $90K. The four quarters Q3 2025–Q2 2026 total $320K. Its first report covers Q3 2025; the issues it reports most are Manufacturing and Medical/Disease Research/Clinical Labs.
Octapharma USA
- Latest quarter
- $90K
- Q2 2026 · 1 reports
- Last 12 months
- $320K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q3 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2025 | $50K | 1 |
| Q4 2025 | $90K | 1 |
| Q1 2026 | $90K | 1 |
| Q2 2026 | $90K | 1 |
Policy issues the reports name
- Manufacturing4 reports
- Medical research and clinical labs4 reports
- Trade4 reports
A report that names several issues counts once for each.
Who was lobbied
- Defense, Dept of (DOD)4 reports
- SENATE4 reports
- Executive Office of the President (EOP)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Cornerstone Government Affairs | $320K | 4 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| DAVID PLANNING | Floor Dir, House Maj Whip; Staff Dir, House Smll Biz Cmte; Spec. Asst to Pres/Leg Affairs, Exec Office of Pres; Dep. Dir Coalitions& Mmbr Services, House Financial Cmte; Floor Asst, House Maj Whip; Spec. Asst, House Chf Dep. Whip; Staff Asst, Speak | Q2 2026 |
| WENDY SAMMONS-JACKSON | Director, Military Infectious Diseases Research Program, US Army Medical Research and Development Command | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/13for Q2 | Cornerstone Government Affairs | $90K |
| 04/15for Q1 | Cornerstone Government Affairs | $90K |
| 01/12for Q4 2025 | Cornerstone Government Affairs | $90K |
| 25/10/16for Q3 2025 | Cornerstone Government Affairs | $50K |
| 25/10/08for Q3 2025 | Cornerstone Government Affairs | Under $5,000 |